Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Kho P, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Brinton L, Buchanan DD, Chanock SJ, Chen C, Chen MM, Cheng THT, Cook LS, Crous‐Bous M, Czene K, De Vivo I, Dennis J, Dörk T, Dowdy SC, Dunning AM, Dürst M, Easton DF, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, García‐Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankinson SE, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hunter DJ, Jones A, Kraft P, Krakstad C, Lambrechts D, Le Marchand L, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Milne RL, Mints M, Nassir R, Otton G, Palles C, Pooler L, Proietto T, Rebbeck TR, Renner SP, Risch HA, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu X, Southey MC, Tham E, Tomlinson I, Trovik J, Turman C, Tyrer JP, Van Den Berg D, Wang Z, Wentzensen N, Xia L, Xiang Y, Yang HP, Yu H, Zheng W, Webb PM, Thompson DJ, Spurdle AB, Glubb DM, O'Mara TA. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal Of Cancer 2020, 148: 307-319. PMID: 32851660, PMCID: PMC7757859, DOI: 10.1002/ijc.33206.Peer-Reviewed Original ResearchConceptsNon-endometrioid endometrial cancerEndometrial cancer riskEndometrial cancerLDL cholesterol levelsMendelian randomization analysisBlood lipidsCholesterol levelsCancer riskRandomization analysisLower endometrial cancer riskNon-endometrioid subtypesHDL cholesterol levelsBlood lipid levelsEndometrial cancer developmentRange of cancersTwo-sample Mendelian randomization (MR) analysisPotential confounding roleHDL cholesterolColorectal cancerLipid levelsObservational studyLower riskGlobal Lipids Genetics ConsortiumCancerInconsistent associations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply